VERAXA Biotech AG (NASDAQ: VRXA), a company focused on designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform. The technology is designed to improve the selectivity of antibody-drug conjugates (ADCs) in cancer treatment by activating therapeutic effects only in targeted tumor cells. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).
The newly released data showed that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, the results suggest a potential for reducing off-target effects commonly associated with traditional ADCs. VERAXA’s proprietary BiTAC approach aims to improve the precision of antibody-based cancer therapies by ensuring that therapeutic effects are confined to malignant cells.
In addition to the BiTAC-ADC platform, VERAXA is also advancing its BiTAC-TCE (T-cell engager) platform. The company maintains a diversified oncology pipeline of antibody-based formats, including ADCs, T-cell engagers, and other antibody-based formats. VERAXA recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp. The company’s newsroom provides the latest updates for investors (https://nnw.fm/VRXA).
The implications of this announcement are significant for the field of oncology. If the BiTAC-ADC platform continues to demonstrate selective activity in further studies, it could lead to more effective cancer treatments with fewer side effects. The ability to spare healthy cells while destroying tumor cells addresses a major limitation of current chemotherapies and some targeted therapies. Moreover, the platform's potential for strategic collaborations could accelerate its development and bring new options to patients sooner.
VERAXA’s presence at the BIO International Convention 2026 underscores its commitment to forging partnerships that can advance its pipeline. The company’s diversified approach, combining multiple antibody-based formats, positions it to address various cancer types and mechanisms. As VERAXA progresses its BiTAC platforms, the oncology community will be watching for further preclinical and clinical data to validate these early findings.
